| Burning mouth syndrome responsive to pramipexol. | |
| | |
MedLine Citation:
|
PMID: 18219443 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings. |
| | |
Authors:
|
J Stuginski-Barbosa; G G R Rodrigues; M E Bigal; J G Speciali |
Related Documents
:
|
19096143 - Foreign accent syndrome mimicked by garcin syndrome with spontaneous resolution. 17686763 - Micromorphology of the labellum and floral spur of cryptocentrum benth. and sepalosaccu... 3363143 - Quadrilateral space syndrome: a rare cause of shoulder pain. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2008-01-25 |
Journal Detail:
|
Title: The journal of headache and pain Volume: 9 ISSN: 1129-2369 ISO Abbreviation: J Headache Pain Publication Date: 2008 Feb |
Date Detail:
|
Created Date: 2008-02-18 Completed Date: 2008-06-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100940562 Medline TA: J Headache Pain Country: Italy |
Other Details:
|
Languages: eng Pagination: 43-5 Citation Subset: IM |
Affiliation:
|
The Department of Neurology, School of Medicine at Ribeirão Preto, Ribeirão Preto, SP, Brazil. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Benzothiazoles / administration & dosage* Burning Mouth Syndrome / drug therapy*, metabolism, physiopathology Corpus Striatum / drug effects, metabolism, physiopathology Dopamine / metabolism Dopamine Agonists / administration & dosage* Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance / drug effects, physiology Female Humans Mouth Mucosa / drug effects*, innervation, physiopathology Parkinson Disease / complications, drug therapy, physiopathology Prospective Studies Receptors, Dopamine D2 / agonists*, metabolism Restless Legs Syndrome / drug therapy, physiopathology Substance Withdrawal Syndrome / physiopathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Benzothiazoles; 0/Dopamine Agonists; 0/Receptors, Dopamine D2; 104632-26-0/pramipexol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sinusitis in children and adolescents with chronic or recurrent headache: a case-control study.
Next Document: Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumo...